Cite
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012
MLA
Margrith E. Mattmann, et al. “Development of Novel M1 Antagonist Scaffolds through the Continued Optimization of the MLPCN Probe ML012.” Bioorganicmedicinal Chemistry Letters, vol. 22, no. 15, May 2012. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a85b9b4efc2c8a3565c032688fcbd69&authtype=sso&custid=ns315887.
APA
Margrith E. Mattmann, Bruce J. Melancon, Christian Sevel, Colleen M. Niswender, Douglas J. Sheffler, Craig W. Lindsley, Michael R. Wood, Yiu-Yin Cheung, P. Jeffrey Conn, Ryan D. Morrison, Thomas J. Utley, J. Scott Daniels, & Thomas M. Bridges. (2012). Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Bioorganicmedicinal Chemistry Letters, 22(15).
Chicago
Margrith E. Mattmann, Bruce J. Melancon, Christian Sevel, Colleen M. Niswender, Douglas J. Sheffler, Craig W. Lindsley, Michael R. Wood, et al. 2012. “Development of Novel M1 Antagonist Scaffolds through the Continued Optimization of the MLPCN Probe ML012.” Bioorganicmedicinal Chemistry Letters 22 (15). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a85b9b4efc2c8a3565c032688fcbd69&authtype=sso&custid=ns315887.